Submitted:
04 August 2023
Posted:
08 August 2023
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Brief Literature Review and General Background
2. Tobacco Economy and Methodology
2.1. Tobacco Cultivation and Land Taxes

2.2. Tobacco Competitive Markets and Their Failures
2.3. Negative Externalities Tax Policies’ Measures
3. The Empirical Approach
3.1. The Design of Taxes in Spain. The Case of Vapers
3.1.1. Brief Methodological Note
3.2. Empirical Approach. The Case of Spain
| Vapers | Combustion Tobacco | |||
|---|---|---|---|---|
| dy/dx | Sign. | dy/dx | Sign. | |
| Sex | -0,001 | -0,042 | *** | |
| Age group (<25) | ||||
| 25-34 | -0,001 | 0,050 | *** | |
| 35-44 | -0,002 | 0,023 | ||
| 45-54 | -0,001 | 0,055 | *** | |
| 55-64 | -0,006 | -0,056 | *** | |
| 65-74 | -0,010 | *** | -0,158 | *** |
| 75-More | . | -0,201 | *** | |
| Migrant | -0,006 | -0,096 | *** | |
| Education (elementary) | ||||
| Basic | 0,004 | *** | 0,041 | *** |
| Medium | 0,009 | *** | 0,037 | *** |
| High | 0,006 | *** | -0,033 | *** |
| Quintile (Q1) | ||||
| Q2 | -0,006 | -0,039 | *** | |
| Q3 | -0,004 | -0,054 | *** | |
| Q4 | -0,009 | *** | -0,067 | *** |
| Q5 | -0,009 | *** | -0,068 | *** |
| Working | 0,001 | -0,001 | ||
| Sport | 0,000 | -0,010 | *** | |
| Social support | 0,000 | -0,053 | * | |
| Observations | 9.093 | 10.357 |
3.3. Health Risk and Costs in Sweden. The Case of Snus
3.3.1. A Brief Review of Previous Literature about Snus
3.3.2. The Impact of Snus on Smoking Prevalence in Sweden
3.3.4. Actual and Hypothetical Health Risks
3.3.5. Actual and Hypothetical Health Costs
- − The number of years a patient suffers from a disease, referred to in health economics as years-lived-with-disability (YLDs).
- − The number of individuals inactive at work because of suffering from a disease multiplied by the smoking-related shares of YLDs from COPD, IHD, lung cancer, and stroke.
- − Labour costs measured by the average labour cost per year combined with smoking-related incapacity to measure productivity loss due to retirement and permanent incapacity.
4. Conclusions
Author Contributions
References
- Nutt, D.J.; Phillips, L.D.; Balfour, D.; et al. (Estimating the harms of nicotine-containing products using the MCDA approach. Eur. Addict. Res. 2014, 20, 218–225. [Google Scholar] [CrossRef] [PubMed]
- Clarke, E.; McNeill, A.; Li, J. Snus: A compelling harm reduction alternative to cigarettes. Harm Reduct. J. 2019, 16, 62. [Google Scholar] [CrossRef] [PubMed]
- Meier, E.; Hatsukami, D.K.; Weaver, M.F.; et al. A randomized clinical trial of snus examining the effect of complete versus partial cigarette substitution on smoking-related behaviors, and biomarkers of exposure. Nicotine Tob. Res. 2020, 22, 473. [Google Scholar] [CrossRef] [PubMed]
- Ramström, L.; Wikmans, T. Mortality attributable to tobacco among men in Sweden and other European countries: An analysis of data in a WHO report. Tob. Induc. Dis. 2014, 12, 14. [Google Scholar] [CrossRef] [PubMed]
- Eurobarometer. Attitudes of Europeans towards tobacco and electronic cigarettes. 2021. Available online: https://health.ec.europa.eu/publications/attitudes-europeans-towards-tobacco-and-electronic-cigarettes-1_en.
- Mallock, N.; Böss, L.; Burk, R.; et al. Levels of selected analytes in the emissions of “heat-not-burn” tobacco products that are relevant to assess human health risks. Arch. Toxicol. 2018, 92, 2145–2149. [Google Scholar] [CrossRef] [PubMed]
- House of Commons. Science and Technology Committee. E-cigarettes (Seventh Report of Session 2017-19). 2018. https://content.tobaccotactics.org/uploads/2019/09/Science-Tech-Committee_E-cigarettes_report-2017-19.pdf.
- Levy, D.T.; Cummings, K.M.; Villanti, A.C.; et al. A framework for evaluating the public health impact of e-cigarettes and other vaporized nicotine products. Addiction 2017, 112, 8–17. [Google Scholar] [CrossRef] [PubMed]
- Chaloupka, F.J.; Sweanor, D.; Warner, K.E. Differential taxes for differential risks: Toward reduced harm from nicotine-yielding products. Am. J. Public Health 2015, 105, 9–11. [Google Scholar] [CrossRef] [PubMed]
- Kao, H.; Huang, C.; Hsieh, M. The health and economic externalities of cigarette smoking in Taiwan. Health Econ. Rev. 2019, 9, 5. [Google Scholar]
- World Health Organization. Tobacco. 2019. Available online: https://www.who.int/news-room/fact-sheets/detail/tobacco.
- Eurostat. European Health Interview Survey (EHIS). 2020. Available online: https://ec.europa.eu/eurostat/web/microdata/european-health-interview-survey.
- Antón, J.I.; Muñoz de Bustillo, R. Health care usage among immigrants and natives in Spain: A count data analysis. Eur. J. Health Econ. 2009, 10, 361–374. [Google Scholar]
- Instituto Nacional de Estadística INE. 2020.
- Ministerio de Sanidad (2022). https://www.sanidad.gob.es/.
- Foulds, J.; Ramström, L.; Burke, M.; et al. Effect of smokeless tobacco (snus) on smoking and public health in Sweden. Tob. Control 2003, 12, 349–359. [Google Scholar] [CrossRef] [PubMed]
- Ramström, L.; Borland, R.; Wikmans, T. Patterns of smoking and snus use in Sweden: Implications for public health. Int. J. Environ. Res. Public Health 2016, 13, 1110. [Google Scholar] [CrossRef] [PubMed]
- Statistiska centralbyrån. Smoking and snuffing: The daily habits of the Swedish people. Stockholm, Sweden: Statistiska centralbyrån. 2002.
- Socialstyrelsen. Socialstyrelsen’s regulations on tobacco products and similar products (SOSFS 2022:4). Stockholm, Sweden: Socialstyrelsen. 2022.
- Vos, K.C.; Faber, T.; Rasmussen, M.; et al. Snus use and risk of alcohol-related harm and mortality: A prospective cohort study. Addiction, 2022, 117, 545–553. [Google Scholar]
- European Commission. Directorate-General for Health and Food Safety. A study on liability and the health costs of smoking. GHK, Reino Unido, tobacco_liability_final_en_0.pdf (europa.eu) 2012.
- Levy, D.T.; Mumford, E.A.; Cummings, K.M.; et al. The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: Estimates of a panel of experts. Cancer Epidemiol. Biomark. Prev. 2004, 13, 2035–2042. [Google Scholar] [CrossRef]
- Hallberg, I.; Schelin, M.E.; Lundell, B. Swedish snus and its possible health effects. Scandinavian Journal of Public Health, 2016, 44, 269–276. [Google Scholar]
- Rehman, A.; Riaz, F.; Waheed, M. Effect of snus (smokeless tobacco) on human health: A systematic review. Cureus, 2020, 12, e9353. [Google Scholar]
- Gouliaev, A.; Forsberg, E.M.; Andersson, G.; et al. The association between Swedish snus and prostate cancer: A nationwide, register-based case-control study. Int. J. Cancer 2021, 149, 355–364. [Google Scholar]
- Persson, E.C.; Schwartz, G.G.; Park, Y.; et al. A prospective study of Swedish snus and risk of intraoral cancers. International Journal of Cancer, 2012, 130, 2412–2417. [Google Scholar]
- Haglund, B.; Eliasson, M.; Stenbeck, M. The epidemiology of snus use in Sweden. Nicotine Tob. Res. 2007, 9, 707–712. [Google Scholar]
- World Health Organization. WHO Report on the Global Tobacco Epidemic; WHO Library: Italy, 2011. [Google Scholar]
| General Practitioner | Hospital | Specialist | ||||
|---|---|---|---|---|---|---|
| Coef. | Sign. | Coef. | Sign. | Coef. | Sign. | |
| Traditional Tobacco | -0,020 | -0,124 | -0,029 | |||
| Vapers | -0,038 | -0,417 | *** | -0,012 | ||
| Sex | 0,053 | *** | -0,596 | *** | 0,015 | |
| Age | 0,024 | *** | 0,062 | 0,005 | ||
| Age^2 | -0,002 | 0,010 | -0,002 | |||
| Migrant | 0,028 | 0,323 | 0,010 | |||
| Sport | -0,016 | *** | -0,116 | *** | -0,006 | *** |
| Marital | 0,016 | -0,149 | * | 0,014 | ||
| Working | -0,066 | *** | -0,332 | *** | -0,020 | |
| Constant | 0,231 | 1,200 | *** | 0,230 | *** |
| Bronchitis | Coronary | Oral | |||||||
|---|---|---|---|---|---|---|---|---|---|
| dy/dx | Std. Err. | Sign | dy/dx | Std. Err. | Sign | dy/dx | Std. Err. | Sign | |
| Sex | -0,003 | 0,004 | - | -0,005 | 0,002 | *** | -0,005 | 0,007 | - |
| Age | 0,005 | 0,003 | - | 0,005 | 0,002 | *** | 0,019 | 0,003 | *** |
| Age^2 | 0,000 | 0,001 | - | -0,001 | 0,000 | *** | -0,001 | 0,001 | ** |
| Traditional Tobacco | 0,023 | 0,006 | *** | 0,002 | 0,004 | ** | 0,058 | 0,008 | *** |
| Vapers | 0,005 | 0,029 | - | 0,012 | 0,011 | - | 0,018 | 0,037 | - |
| Migrant | -0,009 | 0,011 | - | 0,001 | 0,004 | - | 0,023 | 0,012 | ** |
| Sport | -0,003 | 0,001 | *** | 0,000 | 0,000 | - | -0,010 | 0,002 | *** |
| Marital | 0,001 | 0,004 | - | 0,002 | 0,001 | - | 0,001 | 0,004 | - |
| Working | -0,020 | 0,006 | *** | -0,011 | 0,004 | *** | -0,039 | 0,008 | *** |
| Scenario A 1 | Scenario B 2 |
|---|---|
| Smoking prevalence: 10%Snus prevalence: 14% | Smoking prevalence: 23%Snus prevalence: 0% |
| 850.000 people could be smoking in Sweden in 2019 | 1.850.000 people could be smoking in Sweden in 2019 |
| Scenario A | Scenario B | |||
|---|---|---|---|---|
| Non-smokers and non-snus users | Snus users | Smokers | Non-smokers and non-snus users | Smokers (Smokers and snus users from scenario A) |
| No additional risk | Higher health risk compared to non-smokers and non-snus users; lower health risk compared to smokers. | Higher health risk compared to snus users | No additional risk | Higher health risk compared to snus users |
| 140.000 disease cases from COPD, IHD, lung cancer, and stroke in the total population in 2019. | 186.000 disease cases from COPD, IHD, lung cancer, and stroke in the total population in 2019. | |||
| Scenario A | Scenario B |
|---|---|
| Annual treatment costs per case per disease (€) XNumber of disease cases (result from step 1) |
Annual treatment costs per case per disease (€) XNumber of disease cases (result from step 1) |
| Direct costs = 1.5 bn Euro | Direct costs if snus had not been introduced = 1.9 bn Euro |
| Total costs among smokers | Total cost among the total population | ||
|---|---|---|---|
| Cost due to smoking in the scenario A | Increased costs due to smoking in scenario B | Cost due to smoking in the scenario A | Increased costs due to smoking in scenario B |
| 2.10 bn Euro | 4.61 bn Euro | 5.91 bn Euro | 7.61 bn Euro |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).